上海凯宝(300039.SZ)：KBZ24020获批开展用于急性缺血性脑卒中临床试验

Core Viewpoint - Shanghai Kaibao (300039.SZ) has received the Clinical Trial Approval Notice from the National Medical Products Administration for its drug KBZ24020, which is set to undergo clinical trials for the treatment of acute ischemic stroke [1] Company Summary - The clinical trial application for KBZ24020 was accepted on August 25, 2025, and meets the requirements for drug registration [1] - KBZ24020 is derived from clinical experience and is indicated for clearing heat and resolving phlegm, specifically for treating acute ischemic stroke with phlegm-heat syndrome [1] Industry Summary - The drug is aimed at addressing symptoms associated with acute ischemic stroke, including hemiplegia, limb numbness, dizziness, irritability, heavy breath, sticky phlegm in the mouth, yellow tongue coating, and constipation [1]